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ABSTRACT
The myelodysplastic syndromes (MDS) form a heterogeneous group of clonal disorders with an increasing 
incidence in the elderly population and an emerging impact on healthcare resources. MDS are caused 
by gene mutations affecting the haematopoietic stem cells, leading to ineffective haematopoiesis, 
characterised by dysplasia and cytopenia, and a propensity to evolve towards secondary acute myeloid 
leukaemia (AML). Accurate diagnosis and risk assessment are essential for the correct treatment allocation. 
In lower-risk MDS patients, median survival reaches 3–8 years and mortality is mainly caused by cytopenia 
(cardiovascular events, infections, and bleeding). Therefore, the treatment for these patients should be 
focussed on reduction of disease-related complications, disease progression, and improvement of quality 
of life. In contrast, in higher-risk MDS patients, median survival ranges from 1–3 years and death from 
transformation to AML exceeds non-leukaemic mortality. Treatment should be aimed to delay progression 
to AML and improve overall survival. Allogeneic haematopoietic stem cell transplant remains the only 
curative option for higher-risk MDS patients. However, only a minority of patients are eligible for such 
intensive treatment. Consequently, most patients are managed with supportive care and palliative 
treatment, including growth factors, immune-modulators, and hypomethylating agents. Since elderly 
patients with chronic cytopenia are frequently seen in general practice, awareness of the wide spectrum 
of presentations of MDS and potential courses of lower and higher-risk diseases are important for 
primary healthcare physicians. 
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EPIDEMIOLOGY
Myelodysplastic syndrome (MDS) is predominantly 
diagnosed in elderly individuals at a median age >70 
years. In European countries, the age-standardised 
incidence rate amounts to 2–3 per 100,000 patient 
years, with two-fold higher incidence rates in 
males compared to females. The only exception is 
found in MDS with deletion 5q, which has a female 
predominance.1,2-4 The age-specific incidence rate 
in patients >75 years rises over 10-fold, consistent 
with the general increase of cancer-incidence 
observed in the elderly. The age-adjusted incidence 
rate remained stable over recent decades, 
indicating that the observed increase of annual 
case-frequencies is mainly related to ageing and 
not to augmentation of age-specific risks.1 Due to 
an ageing population and increasing diagnostic 
awareness, MDS is likely to become an emerging 
haematological malignancy with a relevant impact 
on healthcare resources in the future.1
PATHOPHYSIOLOGY
MDS is a heterogeneous disease caused 
by accumulation of genetic lesions in the 
haematopoietic stem cell (HSC) compartment.5 
The interaction of extrinsic genotoxic factors with 
intrinsic deficiencies in repairing DNA lesions, 
combined with loss of immunological tumour 
surveillance, are supposed to be responsible for 
the emergence and clonal progression towards 
acute myeloid leukaemia (AML).6 Genetic 
lesions initially identified in MDS were limited to 
structural chromosomal aberrations detectable 
by conventional cytogenetics. However, the 
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understanding of genetic alterations associated 
with MDS/AML has rapidly evolved in recent years.7 
Next-generation sequencing has allowed for the 
discovery of recurrent somatic driver mutations 
(RSDM), comprising genes of RNA-splicing factors, 
epigenetic regulators, transcription factors, 
cell-cycle regulators, cohesin complex factors, and 
cell-signalling molecules (Table 1).8-12 The molecular 
mechanisms and signalling pathways involved in 
the pathogenesis of MDS are very diverse and not 
fully understood. In lower-risk disease, an increased 
cell death rate is the hallmark of ineffective 
haematopoiesis and frequently involves the TP53 
pathway.13 Interactions with cellular (e.g. T cells, 
natural killer cells, myeloid derived suppressor 
cells) and soluble factors (e.g. cytokines, danger 
signals), of the adaptive and innate immunity 
within the microenvironment are additional factors 
contributing to disease initiation and progression.14,15
DIAGNOSTIC APPROACH
The diagnostic approach for primary MDS in adults 
has been reviewed in the European LeukemiaNet 
(ELN) recommendations.8 A thorough patient 
(exposures to genotoxic agents, pesticides, 
insecticides) and family history (signs for germ-
line predisposition for patients <50 years of age) 
is complemented by a physical examination. 
Laboratory analyses are classified as ‘mandatory’ 
(peripheral blood, bone marrow aspirate/
biopsy, cytogenetic analysis), ‘recommended’ 
(fluorescence in situ hybridisation, fluorescence 
activated cell sorting), and ‘suggested’ for specific 
circumstances (single-nucleotide-polymorphism-
array, mutational analysis).
Classification
MDS was initially classified according to the 
French–American–British (FAB) criteria. In 1997, 
a new classification system was proposed by the 
World Health Organization (WHO) and revised 
most recently in 2016.16 In this last revision, the 
historically used expression of ‘refractory anaemia’ 
was replaced by ‘MDS’, due to the fact that MDS 
patients may present with cytopenias other than 
anaemia. Classification of MDS considers the 
number of lineages affected by cytopenia and 
dysplasia, the presence of ring sideroblasts or the 
presence of mutations in SF3B1 (which is associated 
with ring sideroblasts), the number of blasts in 
the peripheral blood or bone marrow, and the 
presence of specific or MDS-defining cytogenetic 
alterations (e.g. del 5q) (Table 2).
Clonal Haematopoiesis in the Elderly 
Unexplained anaemia is present in ~10–15% of 
patients >65 years of age. It is currently an active 
field of investigation to identify patients with 
‘cryptic’ clonal haematopoiesis that may have 
an increased risk for progression towards overt 
Table 1: Recurrently mutated driver genes in MDS.8-12
Selection of the most frequent genes affected by 
RSDM in MDS. Frequencies are only indicative, since 
they are extracted from studies which also included 
myeloid neoplasms other than MDS.
*High association with ringed sideroblasts; ♯Somatic 
and constitutional gene mutations.
RSDM: recurrent somatic driver mutations; MDS: 
myelodysplastic syndromes.
Class Gene Frequency (%)
RNA-splicing 
factors
SF3B1* 25–30
SRSF2 10–15
U2AF1 5–10
ZRSR2 5
SF3A1 1–2
SF1 1–2
U2AF65 1–2
PRPF40B 1–2
Epigenetic 
regulators
TET2 20–25
DNMT3A 5
ASXL1 10–15
EZH2 5
IDH1 1–2
IDH2 1–2
Transcription 
factors
RUNX1♯ 10–20
SETBP1 1–2
NPM1 1–2
ETV6 2
CEBPA♯ 1–2
GATA2♯ 1–2
Cell-cycle 
regulators
TP53 5–10
PTEN 1
CBL 1–2
Cohesin complex 
factors
STAG1 1
STAG2 6
RAD21 1
Cell-signalling 
molecules
NRAS/KRAS 5–10
JAK2 1–2
FLT3 2
CBL 1–2
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haematological malignancies. Patients with 
cytopenia, but without sufficient dysplastic 
changes or MDS-defining cytogenetic alterations, 
are assigned to idiopathic cytopenia of unknown 
significance.17 In such circumstances, observation 
for 3–6 months with repetition of bone-marrow 
analysis prior to diagnosis of MDS is recommended.8 
RSDM can be identified with an increased 
frequency in the elderly (10–20%). These 
individuals have normal peripheral blood values 
or only mild cytopenia that do otherwise 
not fulfill the diagnostic criteria for MDS. 
The condition is termed clonal haematopoiesis with 
indeterminate potential (CHIP: normal peripheral 
blood values with RSDM)18,19 or clonal cytopenia 
with unknown significance (CCUS: cytopenia 
with RSDM),20 respectively. The possibility to use 
next-generation sequencing to identify clonal 
signatures allows the identification of patients at 
early stages and at risk for development of overt 
haematological malignancies. 
GENERAL ASPECTS OF 
MYELODYSPLASTIC SYNDROME 
PATIENT MANAGEMENT 
MDSs are heterogeneous diseases and the natural 
course varies from a chronic, indolent state with 
asymptomatic cytopenia, to a condition with rapid 
evolution towards secondary AML. Two-thirds 
of patients with MDS die of complications 
related to cytopenia and one-third succumb to 
AML progression.21 Management is based on 
disease and patient-related factors using scoring 
systems that have been validated in MDS patients. 
Table 2: World Health Organization (WHO) 2016 classification for myelodysplastic syndromes.16
*Without previous cytotoxic treatment or germline predisposition for myeloid neoplasms; #Cytopenias: 
haemoglobins <100 g/L, thrombocytes <100 g/L, neutrophils <1.8 g/L, monocytes <1 g/L; ◊1% blasts in PB 
must be confirmed with a second value; ⧫≥15%, corresponds to MDS-RS-SLD.
Caveat: If ≥50% are erythroid precursors and ≥20% blast cells of non-erythroid-lineage but <20% of all cells, 
this corresponds now to MDS (MDS-SLD/MLD or EB) and not any more to AML M6 erythroid/myeloid.
MDS: myelodysplastic syndromes; SLD: single lineage dysplasia; MLD: multi lineage dysplasia; 
RS: ringsideroblasts; EB: excess of blasts; RCC: refractory cytopenia of the childhood; wt/mSF3B1: wild 
type or mutated SF3B1; PB: peripheral blood; BM: bone marrow; AR: Auer rods.
Subtype* Number of 
dysplastic
lineages
Number of 
cytopenic 
lineages#
RS of all erythroid 
cells in BM (%)
Blasts in PB or BM
(%) 
Conventional 
cytogenetics
wtSF3B1 mSF3B1 BM PB AR
MDS-SLD 1 1 or 2 <15 <5 <5 <1 -
MDS-MLD 2 or 3 1–3 <15 <5 <5 <1 -
MDS-RS-SLD 1 1 or 2 ≥15 ≥5 <5 <1 -
MDS-RS-MLD 2 or 3 1–3 ≥15 ≥5 <5 <1 -
MDS del(5q) 1–3 1 or 2 n.a. n.a. <5 <1 - Isolated del(5q) with or 
without one additional 
cytogenetic aberration 
without del(7) or -7 
MDS-EB-1 0–3 1–3 n.a. n.a. 5–9 2–4 -
MDS-EB-2 0–3 1–3 n.a. n.a. 10–19 5–19 +
MDS-U - - <15 <5 <5 <1 -
a) 1% blasts in PB 1–3 1–3 n.a. n.a. <5 1◊ -
b) SLD with 
pancytopenia
1 3 n.a. n.a. <5 <1 -
c) defining cytogenetic 
aberration
0 1–3 <15⧫ n.a. <5 <1 - MDS defining 
cytogenetic aberration
RCC 1–3 1–3 <15 <5 <5 <1 -
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Besides age, other patient-related factors include 
comorbidities and frailty, which are increasingly 
recognised as important risk factors, especially 
in elderly patients.8 Accurate diagnosis and risk-
assessment are, therefore, essential for appropriate 
treatment allocation. In lower-risk MDS patients, 
median survival reaches 3–8 years and mortality 
is mainly caused by cytopenia, (cardiovascular 
events, infections, and bleeding.) Therefore, the 
treatment for these patients should be focussed on 
reduction of disease-related complications, disease 
progression, and improvement of quality of life.22,23 
In contrast, in higher-risk MDS patients, median 
survival ranges from 1–3 years and transformation 
to AML exceeds non-leukaemic mortality. Treatment 
should be aimed to delay progression to AML and 
improve overall survival.24,25
Disease-Related Risk Factors
The risk for progression to AML and overall 
survival can be determined by the International 
Prognostic Scoring System (IPSS), the revised IPSS 
(IPSS-R), and the WHO Prognostic Scoring System 
(WPSS).26-28 The numbers of blood lineages affected 
by cytopenia are used in all prognostic-scoring 
systems. Blast count and type of cytogenetic 
alterations are relevant for the IPSS and the IPSS-R, 
whereas the WPSS uses the WHO MDS subtype 
and information on transfusion dependency. Less 
advanced MDS is characterised by <5% of blasts 
in the bone marrow, no circulating blasts in the 
peripheral blood, isolated anaemia, transfusion 
independency, and normal karyotype or favourable 
cytogenetic alterations. In contrast, advanced 
MDS is defined by >5% blasts in the bone marrow, 
circulating blasts, cytopenia of multiple lineages, 
poor-risk or complex cytogenetic alterations, and 
transfusion dependency. 
Patient-Related Risk Factors
In oncological treatment, it is essential to balance 
efficacy against tolerability, which is particularly 
important for elderly and frail patients. Karnofsky 
and Eastern Cooperative Oncology Group (ECOG) 
scores can be used to assess the performance 
status. However, these are influenced by age and, 
therefore, are insufficient to assess comorbidity and 
frailty. The Charlson comorbidity index (CCI) was 
adapted by Sorror et al. for patients undergoing 
allo-haematopoietic stem cell transplantation 
(HSCT)29,30 and also validated for MDS-patients 
(HCT-CI).31 The Italian MDS Study Group simplified 
this scoring system for MDS patients (MDS-CI) 
by considering only cardiac, hepatic, pulmonary, 
and renal comorbidities as well as prior treatment 
for solid tumours.32 Frailty and functionality in 
daily living can be scored with general geriatric 
assessment tools. Based on an increasing cancer 
frequency in elderly patients, as well as a rising 
number of targeted therapies with specific 
side effects, assessment of patient-related factors 
is an emerging requirement for appropriate 
treatment allocation. 
Treatment Approach
Due to the complexity of the disease management, 
MDS patients with symptomatic cytopenia should 
be assessed and followed by physicians with 
experience in the management of MDS. Moreover, 
these patients should be included into prospective 
registries and offered clinical trials, if they fail to 
respond to standard treatment.
Lower-Risk Myelodysplastic  
Syndrome Patients (Figure 1A)
Watchful-waiting
Life expectancy of patients >70 years of age with 
MDS-SLD or MDS with del(5q) is not significantly 
shorter than an age-matched elderly population.28 
Patients with low/intermediate-1 IPSS and 
asymptomatic cytopenia should, therefore, be 
followed regularly without any treatment.8 This 
recommendation might change in the future, as 
molecular testing will recognise higher-risk diseases 
and novel drugs will enter into the therapeutic 
armamentarium that may delay progression.
Supportive treatment
Supportive treatment consists of transfusions, 
infection prophylaxis, antiemetics, analgesics, 
iron chelation, and growth factors. Transfusion 
dependency is generally associated with advanced 
disease stage and worse outcome.28 Many studies 
have been published trying to define the most 
appropriate triggers for transfusions. Transfusions 
of red blood cells (RBC) have been shown 
to improve quality of life and thrombocyte 
concentrates have reduced bleeding events. The 
current general agreement is to transfuse RBC 
if haemoglobin-levels drop <80 g/L, or at higher 
levels if patients are symptomatic due to age or 
other comorbidities. Thrombocyte concentrates 
are prophylactically transfused if thrombocytes 
drop <5–10 g/L, or <20 g/L if additional risk 
factors, such as fever or mucositis, are present. 
Thrombocytes <50 g/L are associated with a 
 HEMATOLOGY  •  August 2017  •  Creative Commons Attribution-Non Commercial 4.0 EMJ  EUROPEAN MEDICAL JOURNAL  HEMATOLOGY  •  August 2017  •  Creative Commons Attribution-Non Commercial 4.0 EMJ  EUROPEAN MEDICAL JOURNAL 108 109
higher bleeding risk in patients treated with 
anticoagulants, although MDS patients may harbour 
thrombocyte dysfunctions or other haemorrhagic 
diathesis and present with major bleeding even 
at higher values. Transfusions are generally 
associated with a higher risk of adverse events such 
as alloimmunisation and transfusion-associated 
complications.33 RBC are generally irradiated in 
patients that are potential candidates for allo-HSCT, 
in order to reduce risk of HLA alloimmunisation and 
transfusion-associated graft versus host disease. 
Controlled trials supporting this approach are, 
however, lacking. 
In heavily transfused patients with >15–20 RBC 
and a ferritin level >1,000 mg/L, iron chelation can 
prevent iron-overload, improve cytopenia, and 
may have an impact on survival.34-36 However, it 
remains a matter of debate which patients should 
be chelated and at what stage of the disease, since 
results from randomised studies are still lacking in 
MDS patients.37 Chelation is generally offered with 
deferasirox (Exjade®) to patients that are candidates 
for allo-HSCT or with a life expectancy >1 year.
Patients with low/intermediate-1 IPSS, with 
haemoglobin-levels <100 g/L, serum erythropoietin 
<200–500 U/L, red cell transfusion independency, 
or <2 RBC units/month are candidates for treatment 
with erythropoietin stimulating agents (ESAs).34,38,39 
No relevant differences have been identified 
between distinct ESA products (recombinant 
human erythropoietin alpha and beta or 
darbepoietin alpha). The required erythropoietin 
dose levels are higher compared to patients 
with renal insufficiency and are usually started 
at 30,000 U/week subcutaneously (~150 ug 
darbepoietin alpha). The dose is doubled after 
6–8 weeks in cases of lack of response. Current 
guidelines suggest addition of granulocytic-colony 
stimulating factor (G-CSF) (at 1-3x300–480 ug/week 
subcutaneously) in those patients with low/ 
intermediate-1 IPSS unresponsive to ESA within 
8–12 weeks.34,40,41 However, large, randomised 
studies supporting this recommendation, especially 
compared to high-dose ESA (60,000 U/week), 
are lacking. The adherence to a strict ESA/G-CSF 
substitution regime is important in order to rapidly 
identify refractory patients that harbor a worse 
prognosis and may be candidates for allo-HSCT 
or clinical trials. Thrombopoietin-stimulating 
agents (TSA) (i.e. romiplostim, eltrombopag) are 
currently tested in clinical trials in patients with 
thrombocytopenia and low/intermediate-1 IPSS. 
TSA show a beneficial effect on platelet count 
and reduction in bleeding without an impact on 
overall survival.42,43 It is important to note that 
ESA and G-CSF are approved for the treatment 
of MDS patients; however, the conditions for 
reimbursement are highly heterogeneous in distinct 
European countries.
Disease-modifying treatment
Immunomodulatory drugs
The anti-cytokine and anti-angiogenetic effect of 
thalidomide was identified to reduce transfusion 
need in MDS patients.44 Due to the long-term 
neurologic toxicity of thalidomide, a 4-amino-
glutarimide derivate, lenalidomide (Revlimid®), 
lacking this side effect, was developed and 
showed sustained transfusion independency and 
cytogenetic responses in about half of all MDS 
patients with low/intermediate-1 IPSS and isolated 
del(5q).45 Response was dependent on additional 
cytogenetic anomalies and transfusion dependency. 
In a Phase III study, about a quarter of non-
del(5q) MDS patients with low/intermediate-1 IPSS 
achieved also transfusion independency, whereas 
mutations in TP53 were associated with resistance 
and disease progression.46,47 The ELN guidelines 
recommend lenalidomide for treatment of i) low/
intermediate-1 IPSS MDS patients with isolated 
del(5q) after failure of ESA treatment, and ii) in 
del(5q) MDS patients with intermediate-1 IPSS 
due to additional cytogenetic anomalies or excess 
of blast. In del(5q) MDS patients with evidence of 
TP53 mutations the choice remains open between 
lenalidomide and other therapies, including 
hypomethylating agents (HMA) and allo-HSCT.34
Immunosuppressive treatment
Ten percent of MDS patients present with 
hypoplastic bone marrow and are potential 
candidates for immunosuppressive treatment 
with antithymocyte globulin (ATG) combined with 
cyclosporine A (CyA). Response rates of around 
one-third can be achieved and responders can 
be predicted based on absence of blasts or ring 
sideroblasts, young age (<60 years), low IPSS, 
short duration of transfusion requirement, and 
HLA-DR15 phenotype.48 The current ELN guidelines 
recommend ATG with 6 months of CyA in younger 
MDS, especially if hypoplastic bone marrow and 
favourable response features are present. No 
recommendation could be made on the duration 
of maintenance therapy in patients responding 
to ATG/CyA.34 The combination with the TSA 
eltrombopag has been shown to improve response 
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rates in aplastic anaemia, but is not approved for 
hypoplastic MDS.49
Higher-Risk Myelodysplastic  
Syndrome Patients (Figure 1B)
Hypomethylating agents
MDS patients with excess of blasts or higher-risk 
scores that are ineligible for intensive chemotherapy 
and allo-HSCT are candidates for palliative 
treatment with HMA. The pyrimidine nucleoside 
analogs 5-azacytidine (AZA) and 5-aza-
2’deoxycytidine/decitabine have been studied in 
Phase III studies in higher-risk MDS patients.50,51 
HMA are generally well-tolerated and showed 
significant higher partial and complete responses 
compared to best supportive care including 
hydroxyurea and low-dose cytosine arabinoside 
(AraC). However, HMA remain inferior to more 
intensive induction chemotherapy followed by 
allo-HSCT, for which, however, only a minority 
of elderly patients are eligible. MDS with 
complex karyotype, either in elderly or younger 
patients without suitable stem-cell donor, should 
preferentially be treated with HMA, due to the 
lower rates of complete remission and higher 
toxicity imparted by intensive chemotherapy.52 
There are no generally accepted predictive 
molecular markers for response to HMA and also 
the duration of treatment remains unclear. Lower 
response rates to AZA have been described for 
patients with previous treatment with AraC, higher 
numbers of bone marrow blasts (>15%) and abnormal 
or complex karyotype. Lower overall survival 
was found in patients with poor performance 
status (ECOG >2), higher cytogenetic risk scores, 
circulating blasts, and high transfusion requirement 
(>4 units over 8 weeks).53 No established treatment 
is currently available after failure to HMA and 
these patients should be offered clinical trials.
A
B
Figure 1: Treatment algorithm for lower and higher-risk myelodysplastic syndromes.8
Allo-HSCT: allogeneic haematopoietic stem cell transplantation; ATG: anti-thymocytic globulin; BM: bone 
marrow; CSA: cyclosporin A; CTx: chemotherapy; ESA: erythropoietin stimulating agent; G-CSF: granulocytic 
colony stimulating factor; mSF3B1: mutated SF3B1; PB: peripheral blood; PS: performance status; RBC: 
red blood cell concentrate; RS: Ringed sideroblasts; sEpo: serum erythropoietin.
Lower-risk IPSS 0, IPSS-R ≤3
Higher-risk IPSS ≥1.5, IPSS-R ≥4.5
Symptomatic anaemia
Age <65–70 years and good PS
Asymptomatic cytopenia
Age ≥65–70 years or poor PS
Watchful waiting
MDS with RS (mSF3B1)
Luspatercept
Hypoplastic MDS
Supportive care Azacytidine
ATG/CyA
MDS del(5q)
Lenalidomid
ESA±G-CSF
Refractory
Allo HSCTAllo HSCTAzacytidine AML-like CTx OR Azacytidine
RBC >2 U/month 
sEPO >500 mU/mL
<10% BM blasts
≥10% BM blasts, no poor CyGPoor CyG
≥10% BM blasts
AML-like CTx OR Azacytidine
No suitable donor
RBC <2 U/month 
sEPO <500 mU/mL
Available donor
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Intensive chemotherapy
Standard AML-based chemotherapy is reserved 
for high-risk MDS patients that are eligible for 
induction chemotherapy before proceeding to 
allo-HSCT. Younger age, good performance status, 
and favourable cytogenetics are independent 
prognostic factors associated with improved 
survival.54 The ELN guidelines recommend induction 
chemotherapy for fit patients, <65–70 years of 
age, without a suitable donor and >10% bone 
marrow blasts but without adverse cytogenetic 
characteristics.8 Patients with adverse or complex 
cytogenetic, as well as mutations or deletions in TP53, 
have a worse response to intensive chemotherapy 
and may be offered treatment with HMA with or 
without subsequent allo-HSCT.52,55 The current 
evidence is insufficient to recommend HMA for 
induction prior allo-HSCT outside of clinical trials.8 
Allogeneic haematopoietic  
stem cell transplantation
Allo-HSCT remains the only curative option but is 
only appropriate for MDS patients considered fit 
for intensive therapy. Assessment of comorbidities 
is important for deciding which patients should 
be referred for allo-HSCT. The HCT-CI can 
estimate non-relapse mortality and is used for this 
purpose.30 Cumulative incidence of treatment-
related mortality (TRM) after allo-HSCT with 
HLA-identical siblings ranges from 32% at 1 year to 
37% at 3 years, the cumulative incidence of relapse 
from 17% at 1 year to 23% at 3 years, and disease-
free survival from 53% at 1 year to 40% at 3 years. 
The international bone marrow transplant registry 
(IBMTR) examined different strategies for patients 
with newly diagnosed MDS. They found that delayed 
transplantation was associated with maximal life 
expectancy, whereas for intermediate-2/high IPSS, 
immediate transplantation was best.56 Age is the 
most important predictive factor for overall survival. 
A retrospective analysis of the European Group for 
Blood and Marrow Transplantation (EBMT) found 
a TRM of 30% in patients <20 years of age, 43% in 
patients 20–40 years of age, and 50% in patients 
>50 years of age.57 However, recent changes in 
conditioning and careful patient selection have 
shown that allo-HSCT is also feasible in patients 
between 60 and 70 years of age. The ELN guidelines 
recommend allo-HSCT for fit patients ≤65–70 
years of age with intermediate-2/high-risk IPSS 
and those with intermediate-1 IPSS with excess of 
blasts or poor risk cytogenetics. For MDS patients 
not eligible for myeloablative conditioning due 
to comorbidities, reduced intensity conditioning 
allo-HSCT should be considered, preferably within 
clinical trials. The EBMT is currently recruiting 
AML/MDS patients for a prospective, randomised 
study to evaluate the significance of allo-HSCT with 
reduced intensity conditioning in patients between 
60 and 75 years of age.
FUTURE DIRECTIONS
The discovery of RSDM opens a broad range of 
novel opportunities by tracking longitudinally clonal 
evolution at early stages of clonal haematopoiesis 
(CHIP and CCUS). Changing classifications and 
the evolving diagnostic tools make disease-based 
risk assessment in MDS patients a dynamic and 
evolving field. Mutations in TP53, EZH2, ETV6, 
RUNX1, and ASXL1 have been shown to confer worse 
prognosis and the presence of mutations in these 
genes increased the accuracy of risk assessment, 
especially in lower/intermediate-1 IPSS patients. 
A molecular based scoring system is currently 
under development and may be incorporated 
into a novel, revised IPSS (IPSS-R mole).58 Lower-
risk MDS patients with ring sideroblasts or SF3B1 
mutations (MDS-RS-SLD/MLS) have been shown 
to respond to luspatercept. This drug scavenges 
tumour growth factor (TGF)-β superfamily ligands 
and improves erythropoiesis by mechanisms distinct 
from erythropoietin. In a Phase II study, luspatercept 
showed interesting erythroid responses ranging 
from 50–90% and led to transfusion independency 
in 30–60% of ESA-refractory patients.59 Based on 
the assumption that low-dose and longer exposure 
of HMA might be more efficient in improving 
differentiation, oral AZA formulations for a 
prolonged period of time are currently being tested 
in clinical studies in lower-risk IPSS MDS patients.60 
Other drugs that are investigated include toll-like 
receptor 2 antibodies, CD95 ligand (FAS-ligand) 
inhibitors, multikinase inhibitors (e.g. rigosertib), 
checkpoint inhibitors (e.g. nivolumab, durvalumab), 
telomerase inhibitors (e.g. imetelstat), and inhibitors 
of mutated IDH1/2 (e.g. AG-120/AG-221). Moreover, 
improvement of treatment allocation based on 
efficacy, tolerability, and affordability remains an 
active field of investigation in the context of health 
services research. The inclusion of MDS patients in 
prospective national and international registries 
is, therefore, highly encouraged. Longitudinal 
observational studies of patients at early stages of 
clonal haematopoiesis with integration of detailed 
health-related and molecular data will be important 
not only to improve our understanding of disease 
biology, but also for prognostication, prediction, 
and allocation to treatment.
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